Agathos backs management buy-out of Hunter Healthcare


HMT LLP advised Agathos on their investment in fast-growing healthcare recruitment business Hunter Healthcare to back the management-buyout. Hunter is a London-headquartered, specialist healthcare recruitment business that places interim and permanent candidates into roles in the NHS, private healthcare and life science sectors. Hunter is known for its niche sector focus, high calibre candidates, depth of market knowledge, and the strength of its relationships with clients. Hunter has developed an exceptional position in healthcare recruitment for non-clinical roles, [...]

Maven VCTs invest in Gen inCode


HMT LLP advised Maven Capital Partners on their investment in Gen inCode, a genetic testing business specialising in the risk assessment and prediction of cardiovascular disease. Founded in 2018, Gen inCode has developed a range of patented DNA risk assessment products which utilise AI, bioinformatics and a globally recognised clinical evidence base to provide predictive analysis of a patient’s health risk. Proprietary algorithms are used to predict the probability of adverse events, resulting in a comprehensive risk evaluation [...]

Biotherapy Services raises funding from Foresight Group


HMT LLP advised specialist pharmaceutical biotech company Biotherapy Services Ltd (“BTS”) on their Series A fundraising. Foresight VCT (“Foresight”) invested £3 million to support the growth of the business supplemented by further investment from existing and new private investors. BTS is a clinical stage, Biopharmaceutical company developing and delivering novel autologous regenerative therapies, currently in clinical development for complex and chronic wounds such as diabetic foot ulcers and pressure sores. The company has developed proprietary expertise and a [...]

ChromaCon AG sold to YMC Co Ltd


Our partner in Switzerland, has advised ChromaCon AG on the sale of their business to YMC Co., Ltd, based in Kyoto, Japan.  ChromaCon will continue to operate as part of the YMC Group of companies. ChromaCon AG, based in Zurich, is a life science tool company. They are a leader in continuous chromatography technologies and market laboratory-scale purification systems employing its process technologies, process simulation and operating software. ChromaCon has pioneered twin-column purification, significantly increasing productivity in large [...]

Investment in Live Better With


HMT LLP advised lead investor Downing Ventures on the £5.4m investment in healthcare e-commerce platform Live Better With. Founded by entrepreneur Tamara Rajah, Live Better With is a healthcare ecommerce platform aimed at helping people with long-term medical conditions. Live Better With’s online marketplace provides access to non-medical products, services and helpful views and information that can make day-to-day life better for those coping with long-term health issues. The Live Better With community has more than 70,000 patients [...]

Disposal of Key2Futures to Horizon


HMT LLP have advised the shareholders of specialist care and support business Key2 Futures Ltd (“Key2”) on the disposal of the business to Horizon Care and Education Group (“Horizon”). Key2 was set up in 2004 to meet the needs of young people leaving local authority care with complex and high support needs. Since then, Key2 have diversified to offer a range of services and expanded to become an important provider across the Midlands and South of England providing housing [...]

Investment in ADC Biotechnology by Maven


 HMT LLP advised Maven Capital Partners (“Maven”) on their investment in anti-cancer drugs manufacturer ADC Biotechnology (“ADC”). ADC Bio operates in the highest growth sector within oncology therapeutics and has developed a unique patented Lock-Release technology for the development and manufacture of Antibody Drug Conjugates (ADC) group of cancer therapies which are designed to specifically target and kill tumour cells. Known as ‘magic bullets’, ADCs are the next generation of anti-cancer drugs which combine the unique targeting capabilities of [...]

Disposal of Foresight Partnership Ltd


HMT LLP advised the shareholders of Foresight Partnership Limited, one of the leading niche governance and organisational development consultancies in healthcare in the UK, on their disposal to GE Healthcare Finnamore. The acquisition will see the launch of the 'Foresight Centre for Governance' at GE Healthcare Finnamore, adding to GE Healthcare Finnamore's specialist health and social care consultancy base.  The Centre will be led by former Foresight shareholders Adrienne Fresko CBE and Sue Rubenstein, who will join as partners reporting [...]

Investment in Disposal Cubicle Curtains Limited by Beringea


HMT LLP advised Beringea LLP (“Beringea”),  the growth capital investor that manages the Proven Venture Capital Trusts, on their £3 million investment in Disposable Cubicle Curtains Limited (“DCCL”), trading as All in One Medical. DCCL manufactures and distributes an evolving range of patented, best in class, disposable curtains and blinds which actively destroy deadly and harmful pathogens.  Distributed to medical institutions, DCCL’s products are manufactured and shipped from its manufacturing plant in Wolverhampton, UK. Part of Beringea’s investment [...]

Disposal of Basan UK Limited


HMT advised Cleanroom Products (Holdings) Limited on the disposal of Basan UK Limited ("Basan"), a leading supplier of cleanroom consumables and equipment for the pharmaceutical, medical, engineering and food industries, to VWR International LLC ("VWR"), a supplier and distributor of scientific supplies to the research laboratory market. Basan, based in Basingstoke, Hampshire, is the UK's largest specialist cleanroom distributor, with 25 years in the cleanroom market and a client base spanning across the pharmaceutical, medical device, biotechnology, microelectronics, [...]

Go to Top